Figure 2
From: Biomolecular imaging of colorectal tumor lesions using a FITC-labeled scFv-Cκ fragment antibody
Molecular imaging of CCSP-2 probe binding in vitro and in vivo. (A) Western blot analysis of CCSP-2 in HCT116 cells transfected with a CCSP-2-encoding plasmid. (B) In vitro confocal images of CCSP-2-overexpressing HCT116 cells and control vector-transfected HCT116 cells treated with FITC-conjugated anti-CCSP-2 scFv. FITC-conjugated kappa isotype control antibody was used as the negative control (magnification: ×630, scale bar: 10 μm). (C) In vivo molecular images of CCSP-2-overexpressing xenograft tumor-bearing mice after the tail vein injection of anti-CCSP-2 scFv-FITC. Data shown are the mean ± SD of at least three independent experiments (*p < 0.05, **p < 0.01, n = 6). (D) Isolated solid tumors acquired from sacrificed mice to examine the fluorescence intensity ex vivo (top) and representative histological and immunofluorescence staining of xenograft tumors (original magnification: ×200, scale bar: 50 μm). (E) Ex vivo biodistribution analysis by fluorescence intensity. Organs were removed from anti-CCSP-2 scFv-FITC-injected mice after 8 h (n = 6).
